Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novasep Acquires Bioprocess Development Specialist and Contract Manufacturer Henogen

Published: Wednesday, July 08, 2009
Last Updated: Wednesday, July 08, 2009
Bookmark and Share
Acquisition of upstream processing capabilities and services enables Novasep to offer full-range of biomanufacturing solutions.

Novasep, a producer of active pharmaceutical ingredients (APIs) and purification technologies for the life science industries, announces today the acquisition of Henogen, a contract manufacturing organization (CMO) offering bioprocess development and manufacturing services from the cell bank to the supply of clinical products.

The move adds a complementary, range of upstream processing capabilities and services to Novasep's comprehensive downstream processing (DSP) offer. Financial terms of the transaction were not disclosed.

As a result of this acquisition, Novasep customers will have access to manufacturing solutions covering almost every type of biopharmaceutical. In particular, Henogen brings its experience with an extensive array of expression tools including E. coli, yeast, L. lactis, insect and mammalian cells as well as viral vectors.

Novasep also becomes one of the few contract manufacturing organizations worldwide able to provide the complete manufacturing solution in the growing field of antibody-drug conjugates, covering early development to future commercial production.

Novasep now offers a combination of solutions for biopharmaceutical manufacturing. These include:
 
• Bioprocess development - both upstream and downstream processing
 
• An out-sourcing solution - contract biomanufacturing services, from the cell bank to the vial
 
• An in-sourcing solution - chromatography and membrane filtration technologies and complete DSP, from lab to industrial scale

"Novasep is making another strategic step forward with the acquisition of Henogen," said Dr Roger-Marc Nicoud, president & CEO of Groupe Novasep SAS. "The two companies have an excellent range of complementary capabilities and we look forward to offering our customers an even wider range of manufacturing services. The move is further confirmation of Novasep's determination to become a major player in the world biomanufacturing market."

"Joining Novasep will provide a boost to the development of our business worldwide," said Dr Jean-François Pollet, CEO of Henogen SA. "We believe the combined offer of our two companies will be very attractive to our existing and future customers."

The two companies have already cooperated on several biomanufacturing projects and together have a strong portfolio of customers including big pharma, mid-size pharma and biotechs. Henogen has more than 100 employee and operates two biomanufacturing facilities south of Brussels. It will become a part of Novasep Process, Novasep's biomolecules division.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep Pushes Further into Japanese Biopharma Market
Stronger local representation in growing Japanese biopharma market will improve Novasep’s capacity to equip and service Japanese clients.
Friday, November 18, 2016
Novasep, Triclinic Labs Partner
Partnership will enable Novasep to offer early-stage solid-state chemistry services in North America.
Thursday, September 15, 2016
Novasep Appoints Dr. François D’Hooge as Bioconjugation Unit Manager
Dr. D’Hooge will manage Novasep’s new antibody drug conjugates (ADC) production facility in Le Mans, France, currently undergoing completion.
Tuesday, September 06, 2016
Novasep and GTP Technology Announces Partnership
Company has announced partnership with GTP Technology for the development of therapeutic and diagnostic candidates for European biopharmaceutical clients.
Friday, March 25, 2016
Novasep, GTP Technology Join Forces
Partnership offers biotech firms full CDMO services at all development stages from gene to end product.
Tuesday, March 22, 2016
Synthesis and Kilo Lab Extensions to US facility
Company builds a new synthesis laboratory and a kilo lab for US facility.
Tuesday, February 09, 2016
Novasep Adds Synthesis and Kilo Lab Extensions to US Facility
Enhanced capabilities bring Novasep’s unique range of specialized drug development technologies within easier reach of North American customers.
Saturday, February 06, 2016
Novasep, Advanced Biotherapeutics Team Up
Strategic partnership creates a world leading CDMO offer to supply AAV-based viral vectors, an increasingly attractive therapeutic platform for gene therapy.
Wednesday, January 13, 2016
Novasep Strengthens its Advisory Board
Professors Alois Fürstner and Alois Jungbauer, renowned experts in catalysis and purification processes, will help boost innovation at Novasep
Tuesday, September 29, 2015
Novasep Invests €10M to Reinforce its Bioconjugation Services
Expansion marks the company’s readiness for full range Antibody Drug Conjugates CMO services.
Thursday, June 25, 2015
Novasep Further Strengthens Management Team
Pierre-Louis Mikus joins as chief legal officer and Bertrand Waymel is promoted to group human resources director.
Wednesday, May 06, 2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
An innovative, genetically-targeted enzyme replacement therapy based on AAV1/SERCA2a.
Thursday, March 26, 2015
Novasep & Celladon Partner
Novasep has entered into an agreement with Celladon, to commercially biomanufacture Celladon’s Mydicar API.
Tuesday, February 24, 2015
Novasep Enters into an Agreement with Celladon
Company selected to commercially biomanufacture Celladon's Mydicar API.
Thursday, February 19, 2015
Novasep Opens New Office in Thailand
Novasep’s extended presence in South East Asia strengthens the company’s ability to address growing needs in the region’s food and feed markets.
Saturday, December 27, 2014
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Transporting Microscopic Cargo Between Human Cells
Scientists have developed a virus-inspired delivery system for material transport between cells.
New Form of Autism Found
An international team of researchers have identified a new form of syndromic autism.
Radiation-Free Imaging in the Brain
Scientists create sensors that use proteins to detect particular targets through induced blood flow changes.
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
BGI Sequences Gingko Tree, Revealing Large, Highly Repetitive Genome
Researchers at BGI have sequenced the more than 10-gigabase ginkgo genome to find a high number of repetitive sequences as well as a number of gene clusters that appear to be involved in defense mechanisms.
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Making Personalized Medicine a Reality
Groundbreaking technique developed at McMaster University is helping to pave the way for advances in personalized medicine.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!